Europäische Union - Deutsch - EMA (European Medicines Agency)

correvio - vernakalant-hydrochlorid - vorhofflimmern - herz-therapie - schnelle konvertierung von den letzten ausbruch vorhofflimmern zu sinusrhythmus bei erwachsenen bei nicht-op-patienten: vorhofflimmern .

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - vernakalantum - konzentrat zur herstellung einer infusionslösung - vernakalanti hydrochloridum 500 mg corresp. vernakalantum 452.5 mg, acidum citricum monohydricum, natrii chloridum, natrii hydroxidum, aqua ad iniectabile ad solutionem pro 25 ml corresp. natrium 78.75 mg. - antiarrhythmikum - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic disorders - herz-therapie - namuscla ist indiziert für die symptomatische behandlung der myotonie bei erwachsenen patienten mit nicht-dystrophischen myotonic disorders.

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europäische Union - Deutsch - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europäische Union - Deutsch - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva sante animale - benazepril hydrochloride - tablette - 5 mg - benazepril hydrochloride 5 mg - benazepril - hund

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva sante animale - benazepril hydrochloride - tablette - 20 mg - benazepril hydrochloride 20 mg - benazepril - hund

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva sante animale - benazepril hydrochloride - tablette - 5 mg - benazepril hydrochloride 5 mg - benazepril - katze

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva sante animale - clindamycin hydrochloride - kautablette - 150 mg - clindamycin hydrochloride 162.9 mg - clindamycin - hund